20:47 , Oct 5, 2018 |  BC Week In Review  |  Company News

BioSense exercises option for Chinese rights to Neovacs's IFNalpha Kinoid to treat lupus

BioSense Global LLC (East Rutherford, N.J.) exercised its option under a 2017 deal to acquire exclusive rights from Neovacs S.A. (Euronext:ALNEV) to develop and commercialize IFNalpha-Kinoid to treat lupus, in China. Neovacs will receive an...
20:07 , Jul 7, 2017 |  BC Week In Review  |  Clinical News

Cara's oral analgesic misses in Phase IIb

Cara Therapeutics Inc. (NASDAQ:CARA) reported top-line data from the Phase IIb CLIN2002 trial in 476 patients with osteoarthritis (OA) of the hip or knee who were experiencing moderate to severe pain showing that twice-daily 1,...
18:41 , Apr 7, 2017 |  BC Week In Review  |  Clinical News

IV CR845: Ph II/III CLIN2101 data

Top-line data from 174 dialysis-dependent chronic kidney disease (CKD) patients with moderate to severe uremic pruritus in the Phase II portion of the double-blind, U.S. Phase II/III CLIN2101 trial showed that IV CR845 met the...
23:03 , Jan 3, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology; dermatology

INDICATION: Pain; itch Mouse and rat studies suggest a G protein-biased KOR agonist could help treat pain and itch without the sedation and dysphoria caused by unbiased KOR agonists. A previously reported triazole-based, biased KOR...
07:00 , Oct 3, 2016 |  BioCentury  |  Finance

Dressed in black

Every single market cap band finished in the black in 3Q16, a feat not accomplished since the first quarter of 2014. M&A and a string of positive clinical and regulatory news fueled the 3Q16 rally...
07:00 , Apr 11, 2016 |  BC Week In Review  |  Clinical News

Subcutaneous beloranib: Additional Phase III data

Additional data from the double-blind, U.S. Phase III bestPWS (ZAF-311) trial in 107 patients with Prader-Willi syndrome showed that twice-weekly 1.8 and 2.4 mg doses of subcutaneous beloranib each met the secondary endpoints of reducing...
08:00 , Feb 22, 2016 |  BC Week In Review  |  Clinical News

Subcutaneous beloranib: Phase IIb data

Data from 66 evaluable Type II diabetics with severe obesity in the double-blind, Australian Phase IIb ZAF-203 trial showed that twice-weekly 1.2 and 1.8 mg subcutaneous beloranib for 6 months each met the primary endpoint...
08:00 , Jan 25, 2016 |  BC Week In Review  |  Clinical News

Subcutaneous beloranib: Phase III data

Last December, FDA placed a full clinical hold on trials of beloranib after a patient was diagnosed with bilateral pulmonary emboli and died in the 6-month, open-label extension portion of bestPWS. In October, FDA placed...
08:00 , Jan 11, 2016 |  BC Week In Review  |  Company News

Neovacs, Chong Kun Dang deal

Neovacs granted Chong Kun Dang exclusive rights to develop and commercialize IFNalpha-Kinoid in South Korea to treat lupus and dermatomyositis. Chong Kun Dang will be responsible for registration of the immunotherapy against interferon (IFN) alpha....
08:00 , Jan 11, 2016 |  BioCentury  |  Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year....